Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alopecia Areata in Children and the Emerging Role of JAK Inhibitors.

Journal of drugs in dermatology : JDD·2026
Same author

Preparing for an ageing Tanzania: cross-sectional study assessing the undergraduate health students' knowledge, attitudes and barriers to geriatric nutrition assessment.

BMJ open·2026
Same author

The Emerging Role of Metformin in Skin Cancer: Mechanistic and Clinical Insights.

Journal of drugs in dermatology : JDD·2026
Same author

Non-tobacco nicotine dependence and rates of postoperative complications in basal cell carcinoma: a retrospective analysis.

Clinical and experimental dermatology·2026
Same author

Visual heuristics and basal cell carcinoma: pitfalls and strategies for clinical vigilance.

Diagnosis (Berlin, Germany)·2026
Same author

Evaluating dermatology appointment lead times with Zocdoc: a cross-sectional study.

Dermatology online journal·2025

Related Experiment Video

Updated: May 26, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

Chemotherapy-induced alopecia.

Susan Y Chon1, Rachel W Champion, Elizabeth R Geddes

  • 1Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. susanchon@mdanderson.org

Journal of the American Academy of Dermatology
|December 20, 2011
PubMed
Summary
This summary is machine-generated.

Chemotherapy-induced alopecia (CIA) is a common side effect of cancer treatment. This review examines the science, research, and management of CIA, highlighting that hair loss patterns are not random and offering patient support resources.

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Related Experiment Videos

Last Updated: May 26, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Chemotherapy-induced alopecia (CIA) is a significant and distressing side effect for cancer patients.
  • Despite its prevalence, CIA is often a neglected area in cancer research, leading to limited advancements in mitigation strategies.
  • Understanding the underlying mechanisms and patient impact is crucial for improving supportive care in oncology.

Purpose of the Study:

  • To provide a comprehensive review of the basic science, clinical research, and current management options for chemotherapy-induced alopecia.
  • To highlight that the patterns and extent of hair loss are not arbitrary.
  • To offer practical resources for patient support and education.

Main Methods:

  • Literature review of basic science research on hair follicle biology during chemotherapy.
  • Analysis of clinical studies investigating the efficacy of various interventions for CIA.
  • Compilation of current clinical guidelines and management strategies.
  • Development of patient support and education materials.

Main Results:

  • Chemotherapy-induced alopecia exhibits specific patterns and extents related to drug type, dosage, and administration.
  • Current management options include scalp cooling, topical treatments, and supportive care, with varying degrees of efficacy.
  • Patient education and psychological support are vital components of managing CIA.

Conclusions:

  • Chemotherapy-induced alopecia is a complex side effect with underlying biological mechanisms that influence its presentation.
  • Further research is needed to develop more effective prevention and treatment strategies for CIA.
  • Improved patient education and support systems can significantly alleviate the distress associated with chemotherapy-induced hair loss.